Edition:
United Kingdom

Fennec Pharmaceuticals Inc (FENC.OQ)

FENC.OQ on NASDAQ Stock Exchange Capital Market

13.01USD
24 Apr 2018
Change (% chg)

$-0.05 (-0.38%)
Prev Close
$13.06
Open
$12.97
Day's High
$13.31
Day's Low
$12.86
Volume
20,131
Avg. Vol
11,449
52-wk High
$14.85
52-wk Low
$8.02

Latest Key Developments (Source: Significant Developments)

Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™.FENNEC PHARMACEUTICALS INC - ‍FDA GRANTED PEDMARK BREAKTHROUGH THERAPY DESIGNATION FOR PREVENTION OF CISPLATIN-RELATED OTOTOXICITY.  Full Article

Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint
Monday, 26 Mar 2018 

March 26 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS.PHASE 3 SIOPEL 6 STUDY MET PRIMARY ENDPOINT.FENNEC - SIOPEL 6 STUDY SHOWED ADDITION OF STS SIGNIFICANTLY REDUCES INCIDENCE OF CISPLATIN-INDUCED HEARING LOSS WITHOUT EVIDENCE OF TUMOR PROTECTION.QTRLY ‍LOSS PER SHARE $0.15​.FENNEC - ‍BELIEVES CASH & CASH EQUIVALENTS ON HAND AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARK (TM) IN H2 2019.  Full Article

Fennec Announces Pricing Of Public Offering
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE.  Full Article

Fennec Pharmaceuticals Q3 loss per share $0.15‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Fennec Pharmaceuticals Inc :Fennec provides business update and reports third quarter 2017 results.Fennec Pharmaceuticals Inc - qtrly loss per share $0.15‍​.Fennec Pharmaceuticals Inc - cash and cash equivalents at Sept 30,2017, $9.7 million versus $3.9 million at Dec 31, 2016‍​.  Full Article

Fennec pharmaceuticals files for stock shelf of up to $90 mln
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Fennec Pharmaceuticals Inc ::Files for stock shelf of up to $90 million - SEC filing‍​.  Full Article

Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Fennec Pharmaceuticals Inc :Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting.Fennec Pharmaceuticals Inc - ‍study met primary endpoint​.Fennec - ‍significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with standard risk hepatoblastoma​.Says ‍treatment was well tolerated and acute toxicity similar and expected between arms​.Fennec Pharmaceuticals Inc - ‍company plans to pursue regulatory approvals with FDA and EMA​.Fennec Pharmaceuticals Inc - co also reported top-line data for secondary endpoints EFS and OS, combination of CIS+STS was generally well tolerated‍​.  Full Article

Fennec Pharmaceuticals posts Q2 loss of $0.06/share
Friday, 12 Aug 2016 

Fennec Pharmaceuticals Inc: Fennec provides corporate update and announces second quarter 2016 results .Qtrly loss per share $0.06.  Full Article

Essetifin announces acquisition of additional shares of Fennec Pharma and filing of its early warning report
Tuesday, 17 May 2016 

Essetifin S.P.A. : Acquired through second closing of non-brokered private placement 1.5 million common shares in capital of fennec pharmaceuticals .Essetifin announces acquisition of additional shares of fennec pharmaceuticals and filing of its early warning report.  Full Article

Fennec Pharmaceuticals posts Q1 loss $0.04/shr
Thursday, 12 May 2016 

Fennec Pharmaceuticals Inc : Fennec provides corporate update and announces first quarter 2016 results .Fennec Pharmaceuticals Inc qtrly loss per share $0.04.  Full Article

Fennec qtrly loss per share $0.04
Thursday, 12 May 2016 

Fennec Pharmaceuticals Inc : Qtrly loss per share $0.04 . Entered into agreement with elion oncology involving transfer by fennec of intellectual property, data relating to eniluracil . Agreement for transfer by co of intellectual property relating to eniluracil,adh-1 technologies,development programs to elion .Fennec provides corporate update and announces first quarter 2016 results.  Full Article

No consensus analysis data available.